The anti‐tumor effects of cosmosiin through regulating AhR / CYP1A1 ‐ PPARγ in breast cancer
The FASEB Journal · 31.08.2024 · 38 (16)
DOI: 10.1096/fj.202401191r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 20.08.2024. Verfasst von Dan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, PPAR gamma, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP1A1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Beijing Xisike Clinical Oncology Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Breast cancer is one of the threatening malignant tumors with the highest mortality and incidence rate over the world. There are a lot of breast cancer patients dying every year due to the lack of effective and safe therapeutic drugs. Therefore, it is highly necessary to develop more effective drugs to overcome breast cancer. As a glycoside derivative of apigenin, cosmosiin is characterized by low toxicity, high water solubility, and wide distribution in nature. Additionally, cosmosiin has been shown to perform anti‐tumor effects in cervical cancer, hepatocellular carcinoma and melanoma. However, its pharmacological effects on breast cancer and its mechanisms are still unknown. In our study, the anti‐breast cancer effect and mechanism of cosmosiin were investigated by using breast cancer models in vivo and in vitro. The results showed that cosmosiin inhibited the proliferation, migration, and adhesion of breast cancer cells in vitro and suppressed the growth of tumor in vivo through binding with AhR and inhibiting it, thus regulating the downstream CYP1A1/AMPK/mTOR and PPARγ/Wnt/β‐catenin signaling pathways. Collectively, our findings have made contribution to the development of novel drugs against breast cancer by targeting AhR and provided a new direction for the research in the field of anti‐breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China.
- Inner Mongolia Key Laboratory of Molecular Biology, Inner Mongolia Medical University, Hohhot, China.
- School of Pharmaceutical Sciences, Peking University, Beijing, China.
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
- Department of General Surgery, Peking University Third Hospital, Beijing, China.
- Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
ORCID-Profile: Dan Wang, Jing Zhang, Ribai Yan, Jinhai Deng, Gang Li, Yan Pan
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, D., Zhang, J., Yin, H., Yan, R., Wang, Z., Deng, J., Li, G., & Pan, Y. (2024). The anti‐tumor effects of cosmosiin through regulating AhR / CYP1A1 ‐ PPARγ in breast cancer. The FASEB Journal, 38(16). https://doi.org/10.1096/fj.202401191r
Vancouver
Wang D, Zhang J, Yin H, Yan R, Wang Z, Deng J, et al. The anti‐tumor effects of cosmosiin through regulating AhR / CYP1A1 ‐ PPARγ in breast cancer. The FASEB Journal. 2024;38(16). doi:10.1096/fj.202401191r
BibTeX
@article{Wang2024,
author = {Wang, Dan and Zhang, Jing and Yin, Houqing and Yan, Ribai and Wang, Zequn and Deng, Jinhai and Li, Gang and Pan, Yan},
title = {The anti‐tumor effects of cosmosiin through regulating AhR / CYP1A1 ‐ PPARγ in breast cancer},
journal = {The FASEB Journal},
year = {2024},
volume = {38},
number = {16},
doi = {10.1096/fj.202401191r}
}
EUVIMED